Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina-Reference-Cited by-同舟云学术

Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina

Published:2005-02 Issue:1-2 Volume:352 Page:217-224
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Li Jian-Jun,Hu Sheng-Shou,Fang Chun-Hong,Hui Rui-Tai,Miao Li-Fu,Yang Yue-Jin,Gao Run-Lin

Publisher

Elsevier BV

Subject

Biochemistry, medical,Clinical Biochemistry,Biochemistry,General Medicine

Reference36 articles.

1. Inflammation, atherosclerosis and ischemic events: exploring the hidden side of the moon;Maseri;N. Engl. J. Med.,1997

2. Atherosclerosis—an inflammatory disease;Ross;N. Engl. J. Med.,1993

3. Novel inflammatory markers of coronary risk: theory versus practice;Libby;Circulation,1999

4. C-reactive protein is not only a marker but also direct cause of cardiovascular disease;Li;Med. Hypotheses,2004

5. Inflammation, aspirin and risks of cardiovascular disease in apparently healthy men;Ridker;N. Engl. J. Med.,1997

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases;Acta Pharmaceutica Sinica B;2024-05

2. A historical, evidence-based, and narrative review on commonly used dietary supplements in lipid-lowering;Journal of Lipid Research;2024-02

3. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice;Fitoterapia;2024-01

4. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP);Progress in Cardiovascular Diseases;2021-07

5. Efficacy and tolerability of a nutraceutical combination of red yeast rice, guggulipid, and chromium picolinate evaluated in a randomized, placebo-controlled, double-blind study;Complementary Therapies in Medicine;2020-01